439117-99-4

Basic information

• Product Name: 1-(N (fluorenylmethoxycarbonyl)-azetidin-2S-yl-carbonylaminomethyl)-2-(tert-butyloxycarbonylaminomethyl)-5-chlorobenzene
• Synonyms: 1-(N (fluorenylmethoxycarbonyl)-azetidin-2S-yl-carbonylaminomethyl)-2-(tert-butyloxycarbonylaminomethyl)-5-chlorobenzene
• CAS NO: 439117-99-4
• Molecular Weight: 576.092
• Mol File: 439117-99-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 1-(N (fluorenylmethoxycarbonyl)-azetidin-2S-yl-carbonylaminomethyl)-2-(tert-butyloxycarbonylaminomethyl)-5-chlorobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(N (fluorenylmethoxycarbonyl)-azetidin-2S-yl-carbonylaminomethyl)-2-(tert-butyloxycarbonylaminomethyl)-5-chlorobenzene(439117-99-4)
• EPA Substance Registry System: 1-(N (fluorenylmethoxycarbonyl)-azetidin-2S-yl-carbonylaminomethyl)-2-(tert-butyloxycarbonylaminomethyl)-5-chlorobenzene(439117-99-4)

Safety Data

• Hazardous Substances Data: 439117-99-4(Hazardous Substances Data)

Upstream product

• 184763-07-3 N-(9-fluorenylmethyloxycarbonyl)-azetidine-2-carboxylic acid 
• 80029-43-2 1-hydroxybenzotriazol-hydrate 
• 439116-15-1 2-(tert-butyloxycarbonylaminomethyl)-5-chlorobenzylamine 
• 439117-41-6 1-azidomethyl-2-(tert-butyloxycarbonylaminomethyl)-5-chlorobenzene 
• 439117-40-5 tert-butyl 4-chloro-2-(hydroxymethyl)benzylcarbamate 
• 439117-38-1 methyl 5-chloro-2-cyanobenzoate 
• 27007-53-0 methyl-2-bromo-5-chlorobenzoate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 136552-06-2 N-(N-(9-fluorenyl)methoxycarbonyl)-L-azetidine-2-carboxylic acid 

Downstream Products

• 439118-00-0 (2-{[(azetidine-2-carbonyl)-amino]-methyl}-4-chloro-benzyl)-carbamic acid tert-butyl ester 

Relevant articles and documents

Low molecular weight thrombin inhibitors with excellent potency, metabolic stability, and oral bioavailability

Modification of lead compound 1 by reducing lipophilicity in the P3 group produced a series of low molecular weight thrombin inhibitors with excellent potency in functional assays, metabolic stability, and oral bioavailability. These modifications led to